What ad­u­canum­ab means for Alzheimer's, un­pack­ing a safe­ty bar­ri­er in CAR-T, the push to up­grade a key ALS tri­al tool, and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

The team has worked hard to bring you the lat­est up­dates from #AS­CO21 based on ab­stract drops. But there are much more in­sights to be gleaned from the ac­tu­al (vir­tu­al) meet­ing. If you’re in­ter­est­ed in the lat­est land­scape of can­cer drug R&D, don’t miss End­points’ AS­CO event. We’ll start off with a round ta­ble dis­cus­sion among some top in­dus­try ex­perts fol­lowed by an in-depth look at BC­MA and where the lead­ers in the field are head­ed. Learn more and sign up here.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA